Accurate Wealth Management LLC Decreases Stock Position in Cencora, Inc. $COR

Accurate Wealth Management LLC decreased its stake in shares of Cencora, Inc. (NYSE:COR) by 24.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 6,653 shares of the company’s stock after selling 2,133 shares during the period. Accurate Wealth Management LLC’s holdings in Cencora were worth $2,233,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Cencora during the 2nd quarter worth $695,215,000. Marshall Wace LLP lifted its position in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares during the last quarter. Mizuho Markets Americas LLC boosted its holdings in shares of Cencora by 116.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock valued at $66,506,000 after buying an additional 1,511,906 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Cencora by 528.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after buying an additional 1,241,186 shares in the last quarter. Finally, Viking Global Investors LP grew its position in shares of Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $312.28 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The stock’s 50 day moving average is $352.05 and its two-hundred day moving average is $340.52. Cencora, Inc. has a twelve month low of $267.40 and a twelve month high of $377.54. The firm has a market capitalization of $60.75 billion, a PE ratio of 37.53, a P/E/G ratio of 1.48 and a beta of 0.68.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.73 EPS. Research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is 28.85%.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on COR. Wells Fargo & Company lifted their price target on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Bank of America cut their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Barclays boosted their price objective on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Evercore reissued an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Twelve investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $403.17.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.